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Abstract
Background: The Belgian Sentinel Network of Laboratories (SNL) was created in 1983 in order to monitor trends
in infectious diseases. Given the evolution of the surveillance system, such as the waivers, fusions and adhesions
of laboratories over time, it is important to evaluate whether the SNL is still fit for purpose. This study aims to
evaluate aspects of the sensitivity and representativeness of the SNL by means of a test coverage analysis.
Methods: We estimated test coverage of the SNL using the ratio of reimbursed tests performed by participating
laboratories to the total number of tests performed between 2007 and 2012, for 12 (groups of) pathogens. We
further evaluated the geographical difference coverage of the SNL at regional and provincial levels.
Results: We found that test coverage of the SNL was stable over time and close to, or greater than, 50 % for the
12 (groups of) pathogens studied. These results hold for the three regions of Belgium but not for all provinces. We
showed that some provinces had a low test coverage for some pathogens and that test coverage was more
variable over time at provincial level.
Conclusions: This sensitivity and representativeness study based on test coverage suggests that the SNL is capable
to describe trend and to monitor changes in the 12 (groups of) pathogens studied both at national and regional
levels. Therefore, the SNL is useful to contribute to estimate the burden of disease and to inform preventive
measures. It should however be reinforced to allow to be used as an alert system at provincial level.
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Background
In spite of the rising contribution of noncommunicable
diseases to the global burden of disease, communicable
diseases continue to threaten population health in high
income countries. Public health authorities seek to
evaluate this threat. In Belgium, a surveillance system
for communicable diseases has been established in 1983
on the basis of a voluntary Sentinel Network of Micro-
biological Laboratories (SNL) [1]. The Scientific Institute
of Public Health (WIV-ISP) coordinates the SNL and
weekly gathers laboratory-diagnosed cases reported by
participating laboratories for more than 30 infectious
diseases. The surveillance system aims to monitor trends
in communicable diseases in order to be able to inform
and alert health authorities on the current epidemio-
logical situation. Its objectives include the uncovering of
geographical and seasonal variations, the detecting of
emerging threats [2], as well as the appraisal of the
effectiveness of preventive measures such as vaccination
[3].
The SNL has evolved over time. Since its creation, the
surveillance system has adapted to the structural reorga-
nisations, fusions, waivers and adhesions of laboratories;
it has accounted for the use of new diagnosis methods
such as PCR amplification; it has integrated European
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case-definitions; and it has encouraged laboratories to
modernise their reporting method, moving from paper-
based reporting to Electronic Data Interchange. Whereas
some of the changes have had a positive impact on the
quality of the surveillance, others might have altered the
ability of the SNL to fulfil its missions. It is therefore im-
portant to regularly evaluate whether the surveillance
system is fit for purpose [4].
To be able to detect changes in the epidemiological
situation, the surveillance system should cover a suitably
large and representative proportion of the Belgian popu-
lation, and ensure that the population under study
remains constant over time [5, 6]. These characteristics
are embraced by two closely related attributes of surveil-
lance systems: sensitivity and representativeness. In the
context of surveillance systems evaluation, sensitivity, in
addition to being a synonym of true positive rate, refers
to the ability of a surveillance system to monitor changes
in the number of cases over time and to detect outbreaks
[6]. Representativeness indicates whether a surveillance
system accurately describes the occurrence of events
under surveillance over time, person and place [6]. Of
particular importance is the ability to equally capture all
infectious diseases under surveillance and to reflect non-
homogeneous distributions of diseases across place. Some
aspects of sensitivity and representativeness can be evalu-
ated using coverage measures which indicate the propor-
tion of the target population included in the surveillance
system. Ideally, the coverage of a surveillance system
should be constant over place and across pathogens to
allow to detect regional outbreaks or specificities, and
stable over time to allow meaningful interpretation of the
time series.
The coverage of the SNL was annually monitored
using the ratio of participating laboratories to the total
number of laboratories. Data indicate constant ratios
over the last 10 years, close to 60 %. The ratios were
constant across Flanders, Wallonia and Brussels, which
gives some indication of the geographical representative-
ness of the SNL. However, these figures are poor proxies
of the coverage of the SNL because the laboratories have
different catchment populations and greatly vary in
terms of size and activity. A better measure of coverage
was presented by Vandenberghe who analysed laboratory
test reimbursement data to estimate test coverage of 15
pathogens. The study revealed that participating labora-
tories were performing more than 50 % of pathogen-
specific tests, and that the test coverage was constant
between 1999 and 2002 [7]. The study also indicated that
participating laboratories were more often connected to a
hospital and tended to conduct more tests as compared to
non-participating laboratories, but were similar with
respect to other characteristics. It is unknown whether
these differences could lead to systematic bias.
Given the evolution of the SNL since 2002, little is
known on whether the coverage of the network remained
constant over the last years. In addition no studies have
evaluated whether the SNL was representative across
place, beyond the three regions of Belgium.
This study aims to evaluate aspects of the sensitivity
and representativeness of the SNL by analysing test
coverage, its geographical distribution, its consistency
across pathogens and its stability over time. We esti-
mated the coverage of the SNL using microbiology tests
reimbursement data between 2007 and 2012, for 12
pathogens or groups of pathogens.
Method
Data
Data on reimbursed microbiology tests were obtained
from the Belgian National Institute for Health and Disabil-
ity Insurance (INAMI-RIZIV) for the period 2007–2012.
The INAMI-RIZIV database contains all microbiology
tests for which laboratories have claimed reimbursement
to the compulsory national social security system. The
database is therefore virtually exhaustive, both over time
and place, with the unlikely exception of tests being
performed without being reimbursed. Microbiology tests
are identified with a nomenclature number that serves for
reimbursement purposes. We also tracked changes in the
INAMI-RIZIV nomenclature over time. We identified
infectious diseases monitored by the SNL for which a
specific reimbursement test was available in the INAMI-
RIVIZ nomenclature [8]. Specific reimbursement codes
(ambulatory and hospital numbers) were found for 8
pathogens - Borrelia, Chlamydia trachomatis, Cryptospor-
idium, Neisseria gonorrhoeae, Hepatitis A, Mycoplasma
pneumoniae, Rotavirus, and Syphilis (Treponema palli-
dum) - and a group of enteric infections including Sal-
monella, Shigella, Yersinia and Campylobacter (Table 1).
Due to privacy concerns, the INAMI-RIZIV did not
provide the number of tests performed for each labora-
tory, but rather aggregated the number of tests by arron-
dissement. To obtain the data, we provided the INAMI-
RIZIV with a list of laboratories, their INAMI-RIZIV
certification code, whether or not they belonged to the
SNL and their postcode. A list was created for each year
in order to account for changes in the accreditation codes
(e.g. following the fusion of laboratories) and in the
participation status to the SNL. We defined annual
participation of a laboratory if it had reported at least one
pathogen to the SNL for a given year. For each year
between 2007 and 2012, we obtained the number of
reimbursed test by nomenclature code and arrondisse-
ment, separately for laboratories participating and not
participating to the SNL. For any nomenclature code, less
than 1 % of the tests failed to be paired with a laboratory
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accreditation code. These tests were excluded assuming
missingness completely at random.
Analysis
Reimbursement data are used to assess aspects of the
sensitivity and representativeness of the SNL by looking
at different measures of test coverage. In the absence of
information on the true number of (diagnosed) cases in
the Belgian population, we used reimbursement data as
a way of proxying case coverage [7]. Test coverage is the
ratio between the number of tests reimbursed by labora-
tories of the surveillance system and the total number of
tests reimbursed. A high test coverage value indicates
that most of the tests performed are captured by the
surveillance system, and therefore, that cases are more
likely to be reported to the surveillance system. Con-
versely, a low test coverage value indicates that most of
the tests are performed by laboratories that do not take
part to the surveillance system and therefore, that cases
are less likely to be reported. We examine the test
coverage of the SNL by pathogen at national level, its
variations by region and province and the stability of the
coverage over time for the period 2007–2012. These
levels of analysis allow to inform on representativeness
by time and place and to indicate whether pathogens are
equally monitored. The extent and stability of test cover-
age values by place and time also informs on sensitivity,
i.e. the ability to monitor change over time at different
geographical levels. It is important to note that this
study is not based on a sample but includes the total
number of tests reimbursed in Belgium for the selected
pathogens. Therefore, we report descriptive statistics
and do not attempt to make statistical inference. Cover-
age values are graphically represented to allow to visually
identify variations over pathogen, place or time.
Results
Number of tests reimbursed by pathogen
The number of tests reimbursed by the INAMI-RIZIV
increased during the period 2007–2012 (Fig. 1). In 2007,
slightly less than 2 million tests were performed to
detect one of the 12 pathogens under study. The num-
ber of tests increased until 2009, then slightly decreased
in 2010, and increased again to reach a value of almost
2.3 million in 2012. The increase is partly due to a
growth of reimbursement for Borrelia tests during this
period. The introduction of a new nomenclature code
for Borrelia in 2008 (Table 1) has led the number of
reimbursed tests to rise from 124,403 in 2007 to 277,805
in 2012. Important increase in the number of reim-
bursed tests is also observed for M. pneumoniae and
Chlamydia; whereas the figures for the group of enteric
infections (Salmonella, Shigella, Yersinia, Campylobac-
ter), Rotavirus and Hepatitis A fluctuate over time.
Table 1 Diagnosis tests by pathogen in the Belgian National
Institute for Health and Disability Insurance nomenclature
(INAMI-RIZIV)
Pathogen Diagnosis test Nomenclature
number
Ambulatory Hospital
Borrelia Search for anti-Borrelia
IgG antibodies
551132 551143
Search for anti-Borrelia
IgM antibodiesa
552134 552145
Search for anti-Borrelia
IgG antibodies, in CSFa
552156 552160
Search for anti-Borrelia
IgM antibodies, in CSFa
552171 552182
Search for anti-Borrelia IgG
antibodies, immunoblot
confirmation testa
552193 552204
Search for anti-Borrelia IgM
antibodies, immunoblot
confirmation testa
552215 552226
Search for anti-Borrelia IgG
antibodies in CSF, immunoblot
confirmation testa
552230 552241
Search anti-Borrelia IgM
antibodies in CSF, immunoblot
confirmation testa
552252 552263
Chlamydia
trachomatis
Chlamydia culture 550675 550686
Chlamydia molecular
amplification
550255 550266
Cryptosporidium Search for cryptosporidium
in stool, after enrichment
549872 549883
Neisseria
gonorrhoeae
Gonorrhoeae molecular
amplification
550911 550922
Aerobic culture 550395 550406
Hepatitis A Search for anti-Hepatitis A
IgM antibodies, non-isotopic
method
551353 551364
Search for anti-Hepatitis A
IgG antibodies
551375 551386
Mycoplasma
pneumoniae
Search for anti-Mycoplasma
pneumoniae IgM antibodies
551891 551902
Search for anti-Mycoplasma
pneumoniae IgG antibodies
551213 551224
Rotavirus Rotavirus diagnosis, for
children younger than
2 years old
552311 552322
Salmonella/
Shigella/Yersinia/
Campylobacter
Stool test 549835 549846
Syphilis
(treponema
pallidum)
Serodiagnosis of treponema 552716 552720
a No reimbursement number before April 2008
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Data also reveal pathogen variations in the number of
tests. Fewer tests are reimbursed for Rotavirus, Chlamydia
and Cryptosporidium (less than 100,000 annually) as com-
pared to M. pneumoniae, Hepatitis A, Gonorrheae and
enteric infections (more than 300,000 annually).
National test coverage
In 2012, the SNL performed the majority of the reim-
bursed tests (Fig. 2). Test coverage was high for all (groups
of) pathogens and ranged from 49.9 % (Borrelia) to 67.5 %
(Rotavirus). Coverage was stable and ranged between
Fig. 1 Evolution of the number of reimbursed tests by (group of) pathogen in Belgium (2007–2012)
Fig. 2 Evolution of the test coverage of the Sentinel Laboratory Network by (group of) pathogen in Belgium (2007–2012)
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approximately 50 and 70 % in the 2007–2012 period.
Average coverage was highest in 2007, decreased a little
until 2010 (see Cryptosporidium), and increased after-
wards to reach a mean value of 58.0 % in 2012 (median
59.9 %).
Regional test coverage
Coverage was high in the three regions and relatively
stable over the whole period (Fig. 3). Between 2007 and
2012 the test coverage of the SNL was highest in Brussels
and lowest in Wallonia for most pathogens. In Flanders,
coverage was close to the national level. In 2012, it ranged
from 61.5 to 82.2 % (median 63.7 %) in Brussels, from
51.2 to 66.6 % in Flanders (median 58.7 %), and from 44.3
to 67.1 % in Wallonia (median 54.1 %). Coverage varied
slightly more over time in Brussels than in the other
regions. In Flanders and Wallonia, coverage was constant
over time for most (groups of) pathogens, with some
yearly variations for Chlamydia and Cryptosporidium.
Overall, results indicate high and constant test coverage
values by (group of) pathogen, region and year.
Provincial test coverage
Variation in coverage was larger at provincial level
(Fig. 4). Coverage was globally lower in Namur, Walloon
Brabant, Liege and Limburg over the 2007–2012 period.
Some pathogens (Borrelia, Chlamydia and Cryptosporid-
ium) indicate great coverage variability between prov-
inces. For instance, the coverage of Cryptosporidium lied
above 90 % in East Flanders and is null in Walloon
Brabant. Other pathogens, showed varying coverage
levels over time for specific provinces, as it is the case
for Chlamydia for which we observe a dramatic increase
in coverage in Namur and Walloon Brabant after 2009.
Overall, coverage varied by (group of) pathogen at
provincial level, but was rather constant over time, with
a few exceptions.
Discussion
We found that test coverage of the SNL was stable over
time and close to, or greater than, 50 % for the 12 patho-
gens or groups of pathogens studied. These results hold
for the three regions of Belgium. For the first time, this
study also allowed to investigate provincial variations in
Fig. 3 Evolution of the test coverage of the Sentinel Laboratory Network by (group of) pathogen and region of Belgium (2007–2012)
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test coverage. We showed that test coverage was con-
stant over time in most provinces, despites a greater
variability in the values.
Results indicate that the SNL is sensitive and represen-
tative for the surveillance of the selected infectious
diseases. Effectiveness of vaccination strategies, seasonal
variations, outbreaks and all sorts of variations in the
occurrence of the pathogens are very likely to be captured
by the surveillance system if they occur at a national or
regional level. The SNL is nevertheless less likely to
capture local changes over time in some provinces such as
Namur, Walloon Brabant, Liege and Limburg.
Variability over time observed in some provinces could
be accounted by changes in the participation status of
laboratories and/or non-concordance between available
accreditation numbers of laboratories and those used in
the INAMI-RIZIV reimbursement database. The latter is
likely to explain the sharp decrease in Namur in 2010
for example.
Regional figures are comparable to those described by
the French Epibac Network in 2010, although the French
network had a higher global coverage, close to 75 % [9].
Comparison with a former study [7] seems to indicate
that the coverage slightly decreased for a few pathogens
(e.g. for Borrelia, Cryptosporidium and Hepatitis A) since
the period 1999–2002. Differences in the results might be
explained by factors such as changes in the reimburse-
ment nomenclature (e.g. Borrelia), changes in the testing
behaviours and changes in the types of laboratories par-
ticipating to the surveillance system (although the propor-
tion of laboratories participating has increased, some
laboratories did quit the network since 2002 and fusions
have been observed). In addition, unlike Vandenberghe
[7], we defined laboratories not sending data as inactive,
even though they officially belonged to the SNL. Our
coverage values are therefore expected to be slightly lower
and closer to reality. Unfortunately, data do not allow to
indicate whether the slight decrease is an artefact or is real
and might therefore have an impact on the trends of noti-
fication rates monitored by the WIV-ISP.
This study has several limitations. First, it relies on the
quality and exhaustively of the reimbursement data, with-
out being able to evaluate it. It is indeed likely that some
tests performed by laboratories to identified pathogens are
Fig. 4 Evolution of the test coverage of the Sentinel Laboratory Network by (group of) pathogen and province of Belgium (2007–2012)
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not included in the INAMI-RIZIV database. Second, our
approach identified laboratories using certification num-
ber for reimbursement. As laboratory identification codes
evolve over time and between sources, some tests could
not be identified in the list of laboratories codes provided
to the INAMI-RIZIV to obtain reimbursement data. In
addition, multiple laboratories associated or belonging to
the same group may share a same laboratory code (e.g.
after a fusion) while not all laboratories from the group
participate to the surveillance network. In this study we
assumed that if at least one laboratory participated to the
SNL, all laboratories from the same group and with the
same identification code were also participating. This
assumption does not always hold which means that cover-
age values could be slightly biased in that respect. Third,
data were only available for a short period of time and do
not allow to assess how changes in test coverage of the
SNL since the 1980s might influence the meaning and
interpretation of the reported number of cases over time.
Data were furthermore only available for 12 pathogens
which are fairly well distributed over place and widely
tested. It is unknown whether results hold for pathogens
which are less often tested (such as Hantavirus) or which
are more clustered or subject to outbreaks (such as
Hepatitis A, Legionella, Neisseria meningitis, or Listeria).
Testing behaviours are also likely to differ by pathogen.
Some tests, such as Syphilis, are systematically prescribed
for some subgroups (e.g. pregnant women). These will
tend to be well reported to the SNL as they are mainly
performed by laboratory hospitals, which are overrepre-
sented in the SNL. In certain circumstances, a high test
coverage, might therefore not translate into representa-
tiveness or sensitivity. Alternative surveillance systems are
therefore available in order to adequately monitor infec-
tious diseases which are not evenly distributed in the
general population, such as sexually transmitted diseases.
In other instances, individuals might perform multiple
tests to diagnose the same disease. This might lead to an
overestimation of the representativeness of the SNL if
these repeated tests are not randomly distributed between
SNL and other laboratories. If, for example, an individual
is diagnosed at multiple university hospitals, which are
known to be more likely to participate to the SNL, the
measure of coverage might slightly be overestimated. The
SNL would however be able to identify duplicates
amongst the reported cases.
This study proved to be useful in showing potential
limitations of the SNL to monitor infectious diseases
with uneven geographical distributions. Results indicate
that better geographical representativeness and sensitiv-
ity could be obtained by recruiting new participating
laboratories in the four provinces where lower test
coverage was detected: Namur, Walloon Brabant, Liege
and Limburg.
Another lesson learned from this study is that one
should be cautious when interpreting data from the
SNL. Analysing provincial notification rates or changes
over time might for example not be relevant for some
pathogens. Automatic representation of provincial data
should therefore be avoided. Rigorous analysis should
preferably rely on multiple sources of data, as recently
illustrated by Sabbe et al. [3] who analysed the impact of
vaccination on rotavirus activity, using a diversity of data
sources such as SNL data, test reimbursement data and
hospitalisation data.
In this study, we evaluated restricted aspects of the
surveillance system and indicated that the SNL, by design,
has sufficient precision and reflects the Belgian situation
without important systematic bias. Many other character-
istics of the SNL have an influence on the capacity of the
surveillance system to effectively monitor infectious
diseases. A wider evaluation of the surveillance system is
therefore strongly recommended in order to have a better
understanding of the actual quality of the data reported by
the SNL [5]. For example, there might be systematic bias
arising from the fact that some participating laboratories
do not report all diagnosed cases, or only report cases for
certain pathogens. Given the evolving nature of the SNL,
the impact of changes in the network characteristics (type
of data transfer, fusion of laboratories, evolution of
pathogen detection techniques, cases definition) should be
systematically documented and continuously assessed.
Obtaining reimbursement data by laboratory, and not by
province, is necessary for that purpose. National Reference
Centre and Obligatory Notification data should also be
used to evaluate the surveillance system.
Through this study, we illustrated the importance of
evaluating (some) attributes of surveillance systems and
showed that available reimbursement data could serve as
a tool for improving the representativeness of a surveil-
lance system in the absence of other data sources. Reim-
bursement data have been underused so far. In the future,
one can think of using reimbursement data together with
the number of reported cases in order to infer the
incidence of a disease. Such a procedure would assume
similar test positivity for participating and non-participating
laboratories, an assumption which deserves to be further
investigated. Having regular reimbursement data by labora-
tory would therefore both allow to monitor the quality of
surveillance and open up new opportunities.
Conclusions
This test coverage study suggests that the SNL is capable
of describing the epidemiological situation and monitoring
changes in the 12 pathogens or groups of pathogens stud-
ied both at national and regional levels. It should however
be reinforced in four out of the 11 provinces to allow to
be used as a sensitive alert system at provincial level.
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